-
Product Insights
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The Human cytomegalovirus 65 kDa Phosphoprotein pipeline market research report provides comprehensive information on the therapeutics under development for PP65, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration...